These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23329850)

  • 41. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
    Durbin AP; Whitehead SS; McArthur J; Perreault JR; Blaney JE; Thumar B; Murphy BR; Karron RA
    J Infect Dis; 2005 Mar; 191(5):710-8. PubMed ID: 15688284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.
    Bauer K; Esquilin IO; Cornier AS; Thomas SJ; Quintero Del Rio AI; Bertran-Pasarell J; Morales Ramirez JO; Diaz C; Carlo S; Eckels KH; Tournay E; Toussaint JF; De La Barrera R; Fernandez S; Lyons A; Sun W; Innis BL
    Am J Trop Med Hyg; 2015 Sep; 93(3):441-453. PubMed ID: 26175027
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
    Torresi J; Heron LG; Qiao M; Marjason J; Chambonneau L; Bouckenooghe A; Boaz M; van der Vliet D; Wallace D; Hutagalung Y; Nissen MD; Richmond PC
    Vaccine; 2015 Sep; 33(39):5127-34. PubMed ID: 26279339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
    Tricou V; Sáez-Llorens X; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Saldaña de Suman O; Montenegro N; DeAntonio R; Mazara S; Vargas M; Mendoza D; Rauscher M; Brose M; Lefevre I; Tuboi S; Borkowski A; Wallace D
    Lancet; 2020 May; 395(10234):1434-1443. PubMed ID: 32197107
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.
    Morrison D; Legg TJ; Billings CW; Forrat R; Yoksan S; Lang J
    J Infect Dis; 2010 Feb; 201(3):370-7. PubMed ID: 20059357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
    Strouts FR; Popper SJ; Partidos CD; Stinchcomb DT; Osorio JE; Relman DA
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004731. PubMed ID: 27214236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.
    Moris P; Bauer KM; Currier JR; Friberg H; Eckels KH; Esquilin IO; Gibbons RV; Innis BL; Jarman RG; Simasathien S; Sun P; Thomas SJ; Watanaveeradej V
    Hum Vaccin Immunother; 2019; 15(9):2090-2105. PubMed ID: 30829100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atypical antibody responses in dengue vaccine recipients.
    Kanesa-Thasan N; Sun W; Ludwig GV; Rossi C; Putnak JR; Mangiafico JA; Innis BL; Edelman R
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):32-8. PubMed ID: 14740953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.
    Sun W; Eckels KH; Putnak JR; Lyons AG; Thomas SJ; Vaughn DW; Gibbons RV; Fernandez S; Gunther VJ; Mammen MP; Statler JD; Innis BL
    J Infect Dis; 2013 Mar; 207(5):700-8. PubMed ID: 23225894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
    Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.
    Sun W; Edelman R; Kanesa-Thasan N; Eckels KH; Putnak JR; King AD; Houng HS; Tang D; Scherer JM; Hoke CH; Innis BL
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):24-31. PubMed ID: 14740952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
    J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.
    Weiskopf D; Angelo MA; Bangs DJ; Sidney J; Paul S; Peters B; de Silva AD; Lindow JC; Diehl SA; Whitehead S; Durbin A; Kirkpatrick B; Sette A
    J Virol; 2015 Jan; 89(1):120-8. PubMed ID: 25320311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.
    Durbin AP; Schmidt A; Elwood D; Wanionek KA; Lovchik J; Thumar B; Murphy BR; Whitehead SS
    J Infect Dis; 2011 Feb; 203(3):327-34. PubMed ID: 21208923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate.
    Anderson KB; Gibbons RV; Edelman R; Eckels KH; Putnak RJ; Innis BL; Sun W
    J Infect Dis; 2011 Aug; 204(3):442-50. PubMed ID: 21742844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.